Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United StatesResearch in context

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United StatesResearch in context

Summary: Background: Pulmonary fibrosis is characterized by lung parenchymal destruction and can increase morbidity and mortality. Pulmonary fibrosis commonly occurs following hospitalization for SARS-CoV-2 infection. As there are medications that modify pulmonary fibrosis risk, we investigated whe...

Full description

Bibliographic Details
Main Authors: Ayodeji Adegunsoye, Rachel Baccile, Thomas J. Best, Victoria Zaksas, Hui Zhang, Rasika Karnik, Bhakti K. Patel, Anthony E. Solomonides, William F. Parker, Julian Solway
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:The Lancet Regional Health. Americas
Subjects:
Pulmonary fibrosis
Post-COVID
Pharmacotherapy
SARS-CoV-2
Rituximab
Online Access:http://www.sciencedirect.com/science/article/pii/S2667193X23001400

Internet

http://www.sciencedirect.com/science/article/pii/S2667193X23001400

Similar Items